Vox Markets Logo
6th November 2024
07:00

Hutchmed China Ltd - Clinical Data to be Presented at ASH and ESMO Asia

31st October 2024
08:30

Hutchmed China Ltd - Total Voting Rights

31st October 2024
08:30

Hutchmed China Ltd - First Commercial Milestone Payment

21st October 2024
08:30

Hutchmed China Ltd - Vesting of awards under the LTIP

16th October 2024
06:00

Hutchmed China Ltd - SAVANNAH: clinically meaningful response rate

24th September 2024
07:00

Hutchmed China Ltd - Japan Approval for FRUZAQLA

9th September 2024
06:00

Hutchmed China Ltd - Clinical Data to be Presented at ESMO and WCLC

30th August 2024
08:30

Hutchmed China Ltd - Total Voting Rights

30th August 2024
06:00

Hutchmed China Ltd - Update on Fruquintinib for Gastric Cancer in China

22nd August 2024
08:30

Hutchmed China Ltd - Standard form for notification of major holdings

21st August 2024
08:30

Hutchmed China Ltd - HUTCHMED to Host Expert Call to discuss ITP

6th August 2024
09:00

Hutchmed China Ltd - LTIP and Share Option Scheme

31st July 2024
11:00

Hutchmed China Ltd - 2024 Interim Results and Business Updates

4th July 2024
06:00

Hutchmed China Ltd - NDA Acceptance in China for Tazemetostat

28th June 2024
11:35

Hutchmed China Ltd - Overseas Regulatory Announcement: Form F-3 Filing

28th June 2024
08:30

Hutchmed China Ltd - Total Voting Rights

28th June 2024
08:30

Hutchmed China Ltd - Blocklisting Six Monthly Return

26th June 2024
08:30

Hutchmed China Ltd - HUTCHMED to Announce 2024 HY Financial Results

HUTCHMED (China) Limited (HCM.L) Share Price & News


Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -M
  • LOW
    -
  • CLOSE
    -
  • SHARES IN ISSUE
    871.04M

HUTCHMED (China) Limited Company Profile

Hutchison China MediTech Limited, known as Chi-Med, is an innovative biopharmaceutical company aiming to become a global leader in the discovery, development and commercialisation of targeted therapeutics and immunotherapies in oncology and autoimmune diseases.

Watchlist